Pd173955

Figure 2 First-generation Bcr-Abl inhibitors. 7.08.5.2.2 Inhibitors of Bcr-Abl The first Bcr-Abl inhibitor to enter clinical development, and the only marketed drug in this area is Novartis's imatinib (1). The discovery of imatinib was a result of judicious optimization of a series of phenylaminopyrimidines that had been identified as inhibitors of the serine threonine kinase PKC-a.82 Further profiling of compound 2 showed that it inhibited a number of other serine threonine and tyrosine...

References

Rosenberg, S. A. Cancer Principles and Practice of Oncology Lippincott-Raven Philadelphia, PA, 1997. 2. American Cancer Society. Cancer Facts and Figures. www.cancer.org (accessed Aug 2006). 3. Hanahan, D. Weinberg, R. A. Cell 2000, 100, 57-70. 4. Vogelstein, B. Kinzler, K. W Nat. Med. 2004, 10, 789-799. 5. Fearon, E. R. Vogelstein, B. Cell 1990, 61, 759-767. 6. Vogelstein, B. Fearon, E. R. Hamilton, S. R. Kern, S. E. Preisinger, A. C. Leppert, M. et al. N. Engl. J....